Old API Wind-down Ltd. Stock

Stocks

ARLZQ

CA03852X1006

Pharmaceuticals

OTC Markets Traded
Delayed OTC Markets 5-day change 1st Jan Change
- USD -.--% Intraday chart for Old API Wind-down Ltd. -.--% -
Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Old API Wind-down Ltd.

Market Cap 87.35K 76.19K 70.49K 66.2K 124K 8.24M 125K 836K 324K 4.05M 328K 321K 14.09M P/E 2016
-2.53x
P/E 2017 -0.75x
Enterprise Value 246M 214M 198M 186M 348M 23.18B 350M 2.35B 911M 11.39B 922M 903M 39.64B EV / Sales 2016
9.18x
EV / Sales 2017 3.22x
Free-Float
100%
Yield 2016 *
-
Yield 2017 -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
-1.21%-3.04%+44.03%+143.07% 980B
-2.48%-5.18%+52.47%+39.15% 550B
-2.14%-4.94%+16.83%+57.08% 382B
+0.25%-3.09%+23.33%+16.04% 316B
+0.61%-1.69%+27.35%+13.73% 272B
+0.22%-3.10%+24.67%+30.49% 268B
+4.59%+1.98%-38.43%-46.26% 199B
-1.19%-4.95%+16.68%+47.69% 182B
-1.35%-1.46%+14.06%+59.26% 154B
Average -0.27%-2.71%+20.11%+40.03% 330.23B
Weighted average by Cap. -0.78%-3.68%+29.49%+63.31%

Financials

2016 2017
Net sales 54.27M 47.33M 43.79M 41.13M 76.86M 5.12B 77.4M 520M 201M 2.52B 204M 199M 8.75B 106M 92.41M 85.49M 80.3M 150M 9.99B 151M 1.01B 393M 4.91B 398M 389M 17.09B
Net income -103M -89.82M -83.09M -78.05M -146M -9.71B -147M -986M -382M -4.77B -387M -378M -16.61B -125M -109M -101M -94.89M -177M -11.81B -179M -1.2B -464M -5.8B -470M -460M -20.2B
Net Debt 209M 183M 169M 159M 297M 19.76B 299M 2.01B 777M 9.71B 786M 769M 33.79B 246M 214M 198M 186M 348M 23.17B 350M 2.35B 911M 11.39B 922M 902M 39.63B
Logo Old API Wind-down Ltd.
Old API Wind-Down Ltd, formerly Aralez Pharmaceuticals Inc., is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company's products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G. Its development products include YOSPRALA and Bilastine. Fibricor (fenofibric acid) is indicated as a complementary therapy along with diet for the treatment of hypertriglyceridemia, and as a complementary therapy along with diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG) and apolipoprotein B (Apo B). Fibricor is also used to increase high-density lipoprotein (HDL) cholesterol (HDL-C) in patients with hypercholesterolemia or mixed dyslipidemia. Cambia (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug (NSAID).
Employees
-
  1. Stock Market
  2. Stocks
  3. ARLZQ Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!